Recent News

• 06.26.2025 - HCW@Home Virtual Fireside Chat
• 06.26.2025 - HCW@Home Virtual Fireside Chat
• 06.13.2025 - A Phase 1, Multicenter, Randomized, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of AMX0114 in ALS (LUMINA)
• 06.10.2025 - Goldman Sachs 46th Annual Global Healthcare Conference 2025
• 06.10.2025 - Goldman Sachs 46th Annual Global Healthcare Conference 2025
• 06.05.2025 - Jefferies Global Healthcare Conference
• 06.05.2025 - Jefferies Global Healthcare Conference
• 06.05.2025 - Survival Results from the Global Phase 3 Trial (PHOENIX) Evaluating Sodium Phenylbutyrate and Ursodoxicoltaurine in ALS
• 06.03.2025 - Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis
• 06.03.2025 - Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis

Recent Filings

• 06.09.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.09.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.09.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.09.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.09.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.05.2025 - 8-K Current report
• 05.27.2025 - 4 Statement of changes in beneficial ownership of securities